PatientSpotlight, by PanaceaIntelPatientSpotlight

Topic · Mental Health

Drug development

Coverage of the development arc of new therapies - trial design, endpoint selection, accelerated vs traditional approval pathways, and what the readouts tell us about where the field is heading. 3 pieces on drug development in Mental Health, newest first within each collection.

← All topics
FilterAll (69)Oncology (10)Rare Disease (9)Immunology (7)Neurology (21)Cardiometabolic (8)Respiratory (5)Women's Health (1)Mental Health (3)Ophthalmology (5)

Signals

2
SignalNEWMay 8, 2026

Treatment-resistant schizophrenia care formalises around clozapine integration

Clozapine pathway formalisation, KarXT muscarinic mechanism integration, and emerging mechanism-targeted programs are reshaping treatment-resistant schizophrenia.

TreatmentPatient journeyInfrastructureDrug development
SignalNEWMay 7, 2026

Cannabis use disorder pharmacotherapy programs reach late-stage trials

Late-stage cannabis use disorder pharmacotherapy programs and integrated behavioural-and-pharmacological care models are emerging in a previously bare category.

TreatmentPipelinePatient journeyDrug development

Explained

1
ExplainedApr 26, 2026FDA · peer-reviewed

How pediatric mental health prescribing differs from adult and why it matters

Pediatric mental health prescribing operates under different evidence frameworks, regulatory expectations, and access structures than adult prescribing. Understanding the differences is essential for any sponsor with mental health assets that are eligible for paediatric expansion or that interact with paediatric-eligible populations.

TreatmentDrug developmentRegulatory